Showing 51-60 of 73 results for "".
Medical Management of Actinic Keratoses and Non- Melanoma Skin Cancer: Disease Progression and Mechanisms of Action of Therapy
https://practicaldermatology.com/topics/general-topics/medical-management-of-actinic-keratoses-and-non--melanoma-skin-cancer-disease-progression-and-mechanisms-of-action-of-therapy/21553/The approach to treatment may be shifting from targeting the lesions we see to addressing an underlying pathology.Advances in Treating NMSC
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advances-in-treating-nmsc/18742/Dr. Goldenberg discusses the benefits of timed sequential therapy using two modalities — destructive therapy followed by field therapy — for actinic keratoses. He also talks about treatment options for advanced basal cell carcinoma, squamous cell carcinoma, and merkel cell carcinoma.Chemoprevention Strategies for AK Patients
https://practicaldermatology.com/topics/skin-cancer-photoprotection/chemoprevention-strategies-for-ak-patients/18822/Neal Bhatia, MD, Chief Medical Editor of Practical Dermatology®, provides strategies for treating actinic keratoses, as well as for prevention and management. He discusses the importance of sun protection and photodamage prevention, and says the key to treatment and maintenance is combination therapNew Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tGalderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million d- Miriam Bettencourt, MD, FAADhttps://practicaldermatology.com/profiles/miriam-bettencourt-md-faad/LbxP4z/Miriam S. Bettencourt, MD, is a board-certified Fellow of the American Academy of Dermatology, a clinical professor of dermatology at the University of Nevada, and an adjunct professor at Touro University. She practices medical and cosmetic dermatology and Mohs surgery at Thomas Dermatology’s Hende…
- Emil Tanghetti, MDhttps://practicaldermatology.com/profiles/emil-tanghetti-md/7N5rqk/He attended U.C Davis where he excelled in his studies and received early admission to UCLA School of Medicine after only three years of undergraduate studies. Upon completing his medical studies and a 1-year pathology fellowship Dr. Tanghetti graduated first in his class and received the Dean Warr…
- ACLARIS files NDA For Novel Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/aclaris-files-nda-for-novel-seborrheic-keratosis-treatment/2458272/Aclaris Therapeutics, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for A-101 40% topical solution (A-101) as a treatment for seborrheic keratosis (SK). If approved, A-101 would be the first FDA-approved t
- Biofrontera Unveils New Red-Light-Emitting Lamp for PDT on Actinic Keratoseshttps://practicaldermatology.com/news/biofronters-unveils-new-red-light-emitting-lamp-pdt-actinic-keratoses/2467140/Biofrontera Inc. announced the launch of the RhodoLED XL, a new red-light-emitting LED lamp approved by the US Food and Drug Administration (FDA) in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy of actinic keratoses of mild-to-moderate sever
- Aclaris Submits Marketing Authorization Application in Europe for A-101 40% for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-submits-marketing-authorization-application-in-europe-for-a-101-40-for-seborrheic-keratosis/2458100/Aclaris Therapeutics, Inc. has submitted a Marketing Authorization Application (MAA) with the Medicines Product Agency (MPA) in Sweden for its product candidate A-101 40% Topical Solution for the treatment of seborrheic keratosis. The MPA will act as the reference member state in this decentraliz